Secure Biometric Cryptosystem for Distributed System

Information (biometric) security is concerned with the assurance of confidentiality, integrity, and availability of information in all forms, biometric information is very sophisticated in terms of all, in this work we are focusing on data pattern along with all security assurance, so that we can improve the matching performance with good security assurance, here one of the most effective RSA algorithm use with biometric (fingerprint) data. Our work includes the determination of appropriate key sizes with security issues and determines the matching performance using MATLAB and JDK1.6, performance of this system is more than 86.7% and when combines this with blind authentication techniques then we get all security assurance with high performance biometric cryptosystem

Learning to Translate with Products of Novices: A Suite of Open-Ended Challenge Problems for Teaching MT

Machine translation (MT) draws from several different disciplines, making it a complex subject to teach. There are excellent pedagogical texts, but problems in MT and current algorithms for solving them are best learned by doing. As a centerpiece of our MT course, we devised a series of open-ended challenges for students in which the goal was to improve performance on carefully constrained instances of four key MT tasks: alignment, decoding, evaluation, and reranking. Students brought a diverse set of techniques to the problems, including some novel solutions which performed remarkably well. A surprising and exciting outcome was that student solutions or their combinations fared competitively on some tasks, demonstrating that even newcomers to the field can help improve the state-ofthe-art on hard NLP problems while simultaneously learning a great deal. The problems, baseline code, and results are freely available.

Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors

<div><p>Purpose</p><p>Cancer outcomes differ depending on where treatment is received. We assessed differences in outcomes in long-term breast cancer survivors at a specialty care hospital by location of their initial treatment.</p><p>Methods</p><p>We retrospectively examined a cohort of women diagnosed with invasive early-stage breast cancer who did not experience recurrence for at least 5 years after the date of diagnosis and were evaluated at The University of Texas MD Anderson Cancer Center between January 1997 and August 2008. The location of initial treatment was categorized as MD Anderson (MDA-treated) or other (OTH-treated). Outcomes analyzed included recurrence-free survival (RFS), distant relapse-free survival (DRFS), and overall survival (OS). The Kaplan-Meier product-limit method was used to compare outcomes between the two groups. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI).</p><p>Results</p><p>We identified 5,091 breast cancer survivors (median follow-up 8.6 years), of whom 89.1% were MDA-treated. The 10-year OS, RFS, and DRFS rates were 90.9%, 88.4%, and 89.0% in the MDA-treated group and 74.3%, 49.8%, and 52.7% in the OTH-treated group, respectively. We observed worse outcomes in the OTH-group in both the univariate analysis and the multivariable analysis (OS: HR = 4.8, 95% CI = 3.9–6.0; RFS: HR = 5.8, 95% CI = 4.8–7.0; DRFS: HR = 5.4, 95% CI = 4.5–6.6).</p><p>Conclusion</p><p>Long-term breast cancer survivors who initiated their treatment at MD Anderson had better outcomes. Location of initial treatment could be an independent risk factor for survival outcomes at specialty care hospitals. This analysis has limitations inherent to retrospective observational studies such as other unmeasured variables may be associated with worse prognosis.</p></div

Demographic and clinical characteristics of breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).

<p>Demographic and clinical characteristics of breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).</p

Kaplan-Meier curves for (A) recurrence-free survival (RFS), (B) distant relapse-free survival (DRFS), and (C) overall survival (OS) for breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).

<p>Kaplan-Meier curves for (A) recurrence-free survival (RFS), (B) distant relapse-free survival (DRFS), and (C) overall survival (OS) for breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).</p

Survival and recurrence outcomes in breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).

<p>Survival and recurrence outcomes in breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).</p